Search research articles
Contact Us
Filters
Showing results (131-140 of 141) with videos related to
Page
of 15
Sort By:
Archives of Dermatological Research
|
June 8, 2024
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
Kim A Papp, Melinda Gooderham, Charles Lynde, et al.
JAMA Dermatology
|
July 17, 2024
Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
Andrew Blauvelt, Emma Guttman-Yassky, Charles Lynde, et al.
Immunotherapy
|
September 1, 2025
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study
Stephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
The Journal of Allergy and Clinical Immunology
|
November 10, 2024
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis
Stephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
Arthritis and Rheumatism
|
August 29, 2009
International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis
Vinod Chandran, Alice Gottlieb, Richard J Cook, et al.
The New England Journal of Medicine
|
October 27, 2023
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Shawn G Kwatra, Gil Yosipovitch, Franz J Legat, et al.
JAMA Dermatology
|
June 25, 2025
Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial
Amy McMichael, Mona Shahriari, Linda Stein Gold, et al.
The New England Journal of Medicine
|
August 13, 2016
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Alexa B Kimball, Martin M Okun, David A Williams, et al.
American Journal of Clinical Dermatology
|
March 31, 2021
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
Tiago Torres, Luis Puig, Ron Vender, et al.
American Journal of Clinical Dermatology
|
August 17, 2022
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study
Tiago Torres, Luis Puig, Ron Vender, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 141) with videos related to
Sort By:
Page
of 15
Archives of Dermatological Research
|
June 8, 2024
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
Kim A Papp, Melinda Gooderham, Charles Lynde, et al.
JAMA Dermatology
|
July 17, 2024
Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
Andrew Blauvelt, Emma Guttman-Yassky, Charles Lynde, et al.
Immunotherapy
|
September 1, 2025
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study
Stephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
The Journal of Allergy and Clinical Immunology
|
November 10, 2024
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis
Stephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
Arthritis and Rheumatism
|
August 29, 2009
International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis
Vinod Chandran, Alice Gottlieb, Richard J Cook, et al.
The New England Journal of Medicine
|
October 27, 2023
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Shawn G Kwatra, Gil Yosipovitch, Franz J Legat, et al.
JAMA Dermatology
|
June 25, 2025
Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial
Amy McMichael, Mona Shahriari, Linda Stein Gold, et al.
The New England Journal of Medicine
|
August 13, 2016
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Alexa B Kimball, Martin M Okun, David A Williams, et al.
American Journal of Clinical Dermatology
|
March 31, 2021
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
Tiago Torres, Luis Puig, Ron Vender, et al.
American Journal of Clinical Dermatology
|
August 17, 2022
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study
Tiago Torres, Luis Puig, Ron Vender, et al.
Page
of 15